AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01916213 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PICSI
Description: If the oocytes are randomized to ICSI during the retrieval they will be ordered by the 1,4,5 8th best oocyte and PICSI to the 2,3, 6 7th best oocytes or the reverse if PICSI is selected. If one cohort is superior that cohort should be chosen by the blinded physician and the alternate cohort frozen or discarded based on their quality. This will ensure that the couple will always have the opportunity to have good quality embryo transferred regardless of how they are randomized. If there are no good quality embryos in the selected cycle we will consider it a failed transfer for that cycle and we will transfer the good quality embryos from the non- selected group as a fresh embryo transfer. For example if a couple is randomized to ICSI and all the ICSI embryos are poor quality but the PICSI embryos are good quality we will consider it a failed ICSI transfer and transfer the PICSI embryos as a fresh embryo transfer.
Study NCT01360749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lambdalina® (Lidocaine 4% cream)
Description: Lambdaline dose: 2 g for 10 cm2.
Study NCT01360749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo dose: 2 g for 10 cm2.
Study NCT03006497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program based on motor learning principles
Description: The exercise program will include simple activities exposing volunteers in various environmental conditions with a view to adjust their head posture in such conditions. The progressiveness of exercises will be based on the two-dimensional classification system of Gentile (1987). Furthermore, external attentional focus will be used.
Study NCT01513161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nalfurafine hydrochloride (TRK-820)
Description: Soft capsule containing 2.5ug nalfurafine hydrochloride. Start with 2.5ug of oral administraion once daily, and can be increased up to 5ug if necessary.
Study NCT01513161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01876030 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES
Study NCT00090480 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HyperAcute - Breast cancer vaccine
Description: Cells will be injected intradermally for four weeks for four cycles. Dosage will vary from 10 million to 100 million HAB cells.
Study NCT04822454 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Night shift shadowing program
Description: Our population, made up of 70 students, was divided into two randomly randomized groups: 31 (44.3%) had five night shift shadowing duty prior to their first official night shifts, and 39 (55.7%) did not participate in the shadowing program.
Study NCT03115203 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle, in patients with sequelae of facial paralysis
Description: Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle, in patients with sequelae of facial paralysis
Study NCT03115203 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle, in healthy subjects
Description: Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle in healthy subjects (data obtained from the SIMOVI project being published).
Study NCT03432754 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Attention Training
Description: The mindfulness-based attention training is closely modeled after the traditional mindfulness-based stress reduction (MBSR) protocol, it incorporates formal MBSR practices such as breath exercises, body scans and long sitting meditations. Specifically, MBAT is an abbreviated version of MBSR with a focus on the cognitive components.
Study NCT03432754 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Education
Description: The control group, which will be used to compare the effects of mindfulness training on emotional and cognitive functioning and mind wandering in older adults, will comprise of scientific health and lifestyle information. Lectures will be focused on concepts presented in the book The Culprit and the Cure: Why lifestyle is the culprit behind America's poor health and how transforming that lifestyle can be the cure. Meetings will cover how to begin and maintain a more nutritious diet, classifying healthy choices across food groups, completing stretching/toning exercises, and reviewing homework.
Study NCT02468414 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MDGN201 TARGTEPO
Description: MDGN201 TARGTEPO secreting EPO (18-25 IU/Kg/day)
Study NCT02468414 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MDGN201 TARGTEPO
Description: MDGN201 TARGTEPO secreting EPO (35-45 IU/Kg/day)
Study NCT02916108 — intervention group
Intervention type: OTHER
Intervention: Reading EEG
Description: EEG recording for 5 minutes (not an intervention)
Study NCT03517956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rogaratinib (BAY1163877)
Description: Dose escalation:~Starting dose is rogaratinib 400 mg twice daily (b.i.d.) in continuous 28-day cycles from Cycle 1 Day 3 onwards.~Dose expansion:~With dose identified in dose escalation part.
Study NCT03517956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib (BAY80-6946)
Description: Dose escalation:~Starting dose is 45 mg on Days 1, 8 and 15 of each 28-day cycle.~Dose expansion:~With dose identified in dose escalation part.
Study NCT03761277 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Medtronic SynchroMed™ II infusion system
Description: Implanted infusion system consisting of a pump and catheter, as well as external components of a clinician programmer, refill and catheter access port kits, and the Personal Therapy Manager (myPTM™).
Study NCT03761277 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Preservative-free morphine sulfate (PFMS)
Description: The pharmacological agent used in the pump for this study is limited to a preservative-free morphine sulfate (PFMS).
Study NCT01950650 — intervention group
Intervention type: BEHAVIORAL
Intervention: No treatment given
Description: Survey conducted through computer-assisted telephone interviewing.
Study NCT01950650 — intervention group
Intervention type: BEHAVIORAL
Intervention: survey
Description: Survey conducted via the Internet.
Study NCT01044862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole (aromatase inhibitor)
Description: A daily dose of 5 mg of the AI, letrozole, will be administered orally for five days starting on day three of the menstrual cycle. Future cycles can be started at 2.5-7.5 mg/d. FDA approval (IND) will be obtained.
Study NCT04199975 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Orthoses
Description: Power-Driven or Mechanical Orthoses
Study NCT03934580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hallucinated meal
Description: a breakfast meal (white bread plus ham and cheese with 250 ml still water) is hallucinated by participants under hypnosis
Study NCT03934580 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Real meal
Description: A real breakfast (white bread plus ham and cheese with 250 ml still water) is consumed by participants
Study NCT01044862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene Citrate
Description: CC will be administered at a dose of 100 mg/d on cycle days 3-7. Future cycles can be started at 50-150 mg/d.
Study NCT01044862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follicle Stimulating Hormone (gonadotropin)
Description: A daily injection of 150 IU of FSH will be administered subcutaneously starting on day three of the menstrual cycle and continuing until the day of hCG administration. Dosage will be able to be increased or decreased 37.5-75 IU/d beginning cycle day 7. Future cycles can be started at doses ranging from 75-225 IU/d. The same type of FSH injections will be used.
Study NCT02521636 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Antibiotic therapy randomization
Study NCT02521636 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy randomization
Study NCT02521636 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serum PCT dosage
Study NCT02789150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine (Levophed)
Description: Titrate norepinephrine to MAP 65-70
Study NCT06795841 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: It was applied for upper respiratory tract over tonsils, trachea, and main bronchi (bilaterally parasternal at the level of angle of Lewis)
Study NCT06795841 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myofascial release therapy
Description: technique was applied from supine position, with both hands cupping both diaphragmatic domes
Study NCT06795841 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: traditional chest physiotherapy
Description: included traditional chest physiotherapy (postural drainage, percussion and shaking), stretching exercise
Study NCT02789150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine (Levophed)
Description: Titrate norepinephrine to MAP 85 or greater
Study NCT04051723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The dexamethasone plus ropivacaine
Description: The local infiltration solution containing 0.25mg Dexamethasone and 2mg ropivacaine per milliliter. The total volume is 20 ml. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
Study NCT01749657 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arizona
Description: Compare custom versus off-the-shelf devices for pain and function in subjects with stage II Posterior Tibial Tendon Dysfunction (PTTD).
Study NCT01749657 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arizona
Description: Compare custom versus off-the-shelf devices for pain and function in subjects with stage II Posterior Tibial Tendon Dysfunction (PTTD).
Study NCT03255967 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DSM-H
Description: Multi-modal quality improvement program for improving the quality of care provided to person with dementia (PWD)-informal caregiver dyads through HHC
Study NCT03255967 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Subjects receive care through usual home healthcare assignment process.
Study NCT00551343 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Exenatide
Description: 10ug Exenatide single s.c. injection
Study NCT02791516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Administered by subcutaneous injection once a month (QM)
Study NCT02791516 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injections once a month
Study NCT04017572 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Automated peritoneal dialysis (APD)
Description: Automated peritoneal dialysis (APD) using the Baxter HomeChoice Pro Cycler.
Study NCT02524275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO
Study NCT02524275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study NCT02524275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02524275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03172884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib (ALIQOPA, BAY80-6946)
Description: 12mg single dose, intravenous on Day 0
Study NCT00467194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Study NCT00467194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT04418492 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills for Adaptive Functioning through Executive training (SAFE; tentative title)
Description: An intervention program to improve adaptive skills and executive functions in young adults with high-functioning autism spectrum disorder was administered weekly for 10 weeks to the participants. The participants also completed pre-, mid- and post-intervention assessments.
Study NCT01037725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5847
Description: Part A - Oral doses given to approximately 6 cohorts of 8 subjects (6 on active and 2 on placebo) on Day 1.~Part B - Oral doses of AZD5847 given to 1 cohort of 8 subjects on Days 1 and 8 in either a fasted state or with a high fat meal
Study NCT01037725 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to AZD5847
Description: In Part A - Single oral doses of AZD5847placebo given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo) on Day 1
Study NCT04470804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus treats in experimental group
Study NCT04470804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine A
Description: Cyclosporine A uses for active comparator group.
Study NCT03760887 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Home exercise program only
Description: After 5 minutes of sensory discrimination (using a 9 point grid) in the clinic patients will perform a home exercise program only
Study NCT03760887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home exercise program and home program of sensory discrimination
Description: After 5 minutes of sensory discrimination (using a 9 point grid) in the clinic patients will perform a home exercise program and two 5 minutes sessions of sensory training at home each day.
Study NCT00519324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10 mg/day (2 tablets of 5 mg each)
Study NCT02985190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine at 75mg/m²/j for 7 days.
Study NCT02991326 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment
Description: The Osteopathic manipulative treatment will follow the approach bellow (using latex gloves for intra oral techniques):~* Compression of the fourth ventricle;~* inhibitory intra-oral pressure technique (IPT) of the temporal muscle;~* inhibition of the inferior head of the lateral pterygoid muscle;~* intra-oral inhibition of the masseter muscle;~* Balanced ligamentous tension (BLT) of the accessory ligaments - sphenopalatine;~* BLT of the accessory ligaments - pterygomandibular raphe;~* sphenopalatine ganglion technique;~* Craniosacral rebalancing;
Study NCT02991326 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham intervention
Description: The sham intervention will be made in the same examination table and the same position, with the use of the latex gloves, to simulate the Osteopathic Manipulative Treatment, only doing simple touches without therapeutic effect intention.
Study NCT02021357 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hyperbolid combined with tongue exercises on the palate
Study NCT02021357 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hyperbolid
Study NCT00156208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: 10mg Tablet, oral Daily for 18 months
Study NCT00156208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: 25 mg Tablet, oral Daily for 18 months
Study NCT03683030 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-Electrode RF Balloon Catheter
Description: Multi-Electrode RF Balloon Catheter will be inserted
Study NCT04516759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: 50mg film-coated tablets (at daily dose of 100mg BID)
Study NCT04516759 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo tablets
Study NCT00174252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genotonorm (Somatropin)
Description: 0.40 mg/kg/week dived in 7 daily subcutaneous injections during 2 years
Study NCT06395571 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Goat milk-based infant formula
Description: Goat milk-based infant formula fed at age appropriate quantities for 24 weeks
Study NCT06395571 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cow's milk-based infant formula
Description: Cow's milk-based infant formula formula fed at age appropriate quantities for 24 weeks
Study NCT01182649 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: coronary stent
Description: coronary angioplasty with stent implantation
Study NCT01182649 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stent
Description: coronary angioplasty with stent implantation
Study NCT00811941 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: as-needed use, tablets, orally, 52 weeks
Study NCT00811941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalmefene
Description: 18.06 mg as-needed use, tablets, orally, 52 weeks. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.
Study NCT02377700 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xeltis Vascular Patch, Model COR-VP-001
Description: The intended use of the Xeltis Vascular Patch, Model COR-VP-001 is to augment pulmonary artery and thereby improve hemodynamics by increasing blood flow to the lungs in patients with congenital pulmonary artery obstructions as an initial part of the staged procedure of a bidirectional cava-pulmonary anastomosis
Study NCT01318694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisporivir
Description: ALV 200 mg soft gel capsules administered orally
Study NCT02840474 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB080-00-AB
Description: VRC01LS is an investigational human monoclonal antibody targeted to the CD4+ binding site of HIV-1.
Study NCT02840474 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB075-00-AB
Description: VRC07-523LS is an investigational human monoclonal antibody targeted to the CD4+ binding site of HIV-1.
Study NCT04051723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The ropivacaine
Description: The local infiltration solution containing 2mg ropivacaine per milliliter. The total volume is 20 ml. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
Study NCT00187876 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL reconstruction control
Description: The intervention consists of the reconstruction of the ACL ligament using patellar tendon allografts that have undergone the BioCleanse™ process.
Study NCT06796088 — intervention group
Intervention type: OTHER
Intervention: Treated zones exposed to Visible Light source
Description: The treated zones were exposed to Visible Light to induce skin pigmentation (144J/cm2), 15 to 30 minutes after application.
Study NCT06796088 — intervention group
Intervention type: OTHER
Intervention: Untreated zone exposed to Visible Light source
Description: The untreated zone was exposed to Visible Light to induce skin pigmentation (144J/cm2), as the same time as the treated zones.
Study NCT06794788 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR-The iWear
Description: The immersive virtual reality device was used for this study from(Vuzix®, Rochester, New York, USA). The iWear consists of a lightweight high-end pair of video headphones that contain pair of VR goggles
Study NCT00025207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Given orally
Study NCT00025207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02701283 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Transcatheter Aortic Valve Replacement Systems
Description: Treatment of severe aortic stenosis in subjects who have a low predicted risk of operative mortality for SAVR with Medtronic TAVR Systems
Study NCT02701283 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Aortic Valve Replacement (SAVR)
Description: Treatment of severe aortic stenosis in subjects who have a low predicted risk of operative mortality for SAVR with a commercially approved surgical bioprothesis
Study NCT01258933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: 300 mg Dose 1, then 1,000 mg weekly x 7, (treatment) then 1,000 mg every 2 months beginning on week 12
Study NCT02902302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg/10 mL oral suspension
Study NCT02902302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MOMENT 400 mg coated tablet